PCA
JAZZ icon

Pallas Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pallas Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Buy
1,979
+659
+50% +$144K 0.01% 585
2026
Q1 		$250K Buy
+1,320
New +$231K 0.01% 694

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Pallas Capital Advisors's JAZZ Position: Q2 2026 in Review

Pallas Capital Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 50% in Q2 2026, buying an estimated $144K and bringing the position to 1,979 shares worth $477K. The position accounts for 0.01% of the portfolio, ranked #585.

Pallas Capital Advisors first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Pallas Capital Advisors held 1,979 shares of Jazz Pharmaceuticals worth $477K as of Q2 2026.
  • Pallas Capital Advisors bought 659 Jazz Pharmaceuticals shares in Q2 2026, an estimated $144K.
  • Jazz Pharmaceuticals made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #585 holding.
  • Pallas Capital Advisors first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.